Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2009.543 | Patients at High Cardiovascular Risk Lack Awareness of the Importance of Risk Factor Modification and the Dire Consequences Associated with Peripheral Artery Disease : A cross sectional cohort study | Prof. YAN Bryan Ping Yen |
| 2013.607 | Dyslipidemia International Study II (DYSIS II) | Dr Yan Bryan Ping Yen |
| 2018.382 | ILUMIEN IV: OPTIMAL PCI OPtical Coherence Tomography (OCT) Guided Coronary Stent IMplantation Compared to Angiography: a Multicenter Randomized TriaL in PCI |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2018.393 | Validation of a cuffless blood pressure device for 24-hours ambulatory blood pressure monitoring |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2020.082 | A Non-randomized, Clinical Registry of the DynamX Novolimus Eluting Coronary Bioadaptor System in the Treatment of Patients with De Novo Native Coronary Artery Lesions |
Prof. YAN Bryan Ping Yen 甄秉言教授 |
| 2019.004 | Multi-center cross-sectional epidemiological study to characterize the prevalence and distribution of lipoprotein(a) levels among patients with established cardiovascular disease |
Prof. YAN Bryan Ping Yen 甄秉言教授 |
| 2018.214 | XIENCE 28 Global Study |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2019.571 | Gaps In Awareness of Peripheral Arterial Disease in Hong Kong: A Cross Sectional Study |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2018.299 | Lipid management status of patients with ischemic stroke (IS) in Hong Kong | Prof. YAN Bryan Ping Yen |
| 2018.442 | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects with Acute Coronary Syndrome |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2018.215 | Electrical Activation Mapping Guided Cardiac Resynchronization Therapy for Nonresponders | Prof. YAN Bryan Ping Yen |
| 2020.154 | BIOFLOW-DAPT: BIOTRONIK – A Prospective, Randomized, Multi-center Study to Assess the SaFety of the Orsiro Mission Stent compared to the ResoLute Onyx Stent in Subjects at High Risk for Bleeding in combination With 1-month Dual AntiPlatelet Therapy |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2020.080 | A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein (a) lowering with TQJ230 on major cardiovascular events in patients with established cardiovascular disease |
Prof. YAN Bryan Ping Yen 甄秉言教授 |
| 2018.304 | Achievement of cardiovascular risk factor goals and target levels in patients at very-high and high cardiovascular risk in Hong Kong |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2019.346 | HD Mapping Observational Study |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2019.357 | Prolonged Ambulatory Heart Rate Variability Monitoring to Predict Major Adverse Cardiac Events in High-risk Patients with Cardiovascular Diseases |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2019.653 | In-Depth Analyses of 12-lead ECG P-wave Indices Using Machine Learning to Predict Atrial Fibrillation and Cardiovascular Events |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2020.448 | Rationale and Design of DAbigatran for Stroke PreVention In Atrial Fibrillation in MoDerate or Severe Mitral Stenosis (DAVID-MS): A Randomized, Open-label study |
Prof. YAN Bryan Ping Yen 甄秉言教授 |
| 2019.021 | Activation Pattern and Acute Hemodynamics of His and Left Bundle Pacing | Prof. YAN Bryan Ping Yen |
| 2021.459 | BioFreedom Ultra Stent in Hong Kong All Comers Registry |
Prof YAN Bryan Ping Yen 甄秉言 |
| 2022.335 | Evaluation of the Relationship Between Arterial Stiffness and Coronary Artery Disease by Stroke-Volume-Allocation |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2022.162 | A Multicenter, Cross-sectional Study to Characterize the Distribution of Lipoprotein(a) Levels Among Patients With Documented History of Atherosclerotic Cardiovascular Disease (ASCVD) |
Prof. YAN Bryan Ping Yen 甄秉言教授 |
| 2022.497 | In-hospital initiation of Angiotensin–Neprilysin Inhibition for the treatment of acute heart failure regardless of ejection fraction: An open labelled randomized study | Prof. YAN Bryan Ping Yen |
| 2022.501 | The effect of early inpatient initiation of Dapagliflozin on the Health-related Quality of Life of patients with heart failure with all range of Ejection Fraction: a Local Registry | Prof. YAN Bryan Ping Yen |
| 2022.502 | Development of Fluorescence Probes and Nanomaterial for Plaque and Thrombosis Imaging in Patients | Prof. YAN Bryan Ping Yen |
| 2023.362 | A Phase 3 Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-0616 in Reducing Major Adverse Cardiovascular Events in Participants at High Cardiovascular Risk |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2021.637 | Drug-Coated Balloon for the Treatment of De Novo and Restenotic Coronary Artery Lesion: a prospective observational study |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2022.164 | A Study on Outcomes of Surgical and Percutaneous Left Atrial Appendage Closure |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2023.296 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK‑0616 in Adults With Heterozygous Familial Hypercholesterolemia |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2022.573 | Patient-Perceived Versus Actual Risk of Cardiovascular Disease and Willingness to Follow Recommendations for Cardiovascular Prevention | Prof. YAN Bryan Ping Yen |
| 2023.464 | Time-trend analysis of clinical characteristic and outcomes in patients with unprotected left main coronary artery disease treated with PCI over a 10-year period from year 2010 till year 2020. | Prof. YAN Bryan Ping Yen |
| 2024.156 | A Phase 3, Open-label Extension Study to Evaluate the Safety and Efficacy of MK-0616 in Adults With Hypercholesterolemia |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2021.457 | Develop multi-modal spectroscopy (MMS) & biosensor platforms for monitoring cardiovascular diseases (CVDs) |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2022.449 | A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein (a) |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2021.718 | The effects and cost-effectiveness of a technology-based family-centered empowerment (T-FAME) program on health and health service utilization outcomes of post-discharged patients with advanced heart failure: A sequential mixed method study |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2021.717 | In-hospital initiation of empagliflozin for the treatment of new-onset acute heart failure regardless of ejection fraction: A Pilot Study |
Prof. YAN Bryan Ping Yen 甄秉言教授 |
| 2022.409 | Validation of Pulse Sensors for Cardiovascular Disease Management |
Prof. YAN Bryan Ping Yen 甄秉言教授 |
| 2022.287 | Validation of a novel device for screening patients with atrial fibrillation / arrhythmia | Prof. YAN Bryan Ping Yen |
| 2023.577 | Switching Sildenafil to Riociguat in Chronic Thromboembolic Pulmonary Hypertension (CTEPH) after balloon pulmonary angioplasty (BPA) | Prof. YAN Bryan Ping Yen |
| 2023.316 | A Prospective Randomized Multicenter Single Blinded Study to Assess the Safety and Efficacy of the SELUTION SLR™ 018 Drug Eluting Balloon in the Treatment of Subjects With Femoropopliteal Artery Lesions |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2022.065 | Real World Effectiveness of Evolocumab among Chinese Patients in Hong Kong | Prof. YAN Bryan Ping Yen |
| 2022.038 | Prevalence of LVEF non-recovery after acute myocardial Infarction |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2023.186 | Investigation of the adverse effects of antiviral compounds |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2023.041 | A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovascular events in high-risk primary prevention patients (VICTORION-1 PREVENT) |
Prof. YAN Bryan Ping Yen 甄秉言教授 |
| 2023.194 | A Prospective Randomized Multicenter Single Blinded Study to Assess the Safety and Effectiveness of the SELUTION SLR™ 014 Drug Eluting Balloon in the Treatment of Below-the-Knee (BTK) Atherosclerotic Disease in Patients With Chronic Limb Threatening Ischemia (CLTI) |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2024.212 | Retrospective Database Study for Treatment Patterns of Lipid-lowering Therapy in Patients with Hypercholesterolemia or Mixed Dyslipidemia in Hong Kong, South Korea, and Taiwan (READY Study) |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2024.152 | Rationale and design of Dabigatran for Mitral Stenosis Atrial Fibrillation Trial |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2024.251 | BIOTRONIK – Safety and Clinical Performance of the Drug Eluting Resorbable Coronary MAGnesium Scaffold System (Freesolve) in the Treatment of Subjects with de Novo Lesions in Native Coronary Arteries: BIOMAG-II: A randomized controlled trial |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2024.468 | AI-Based Intima-Media Thickness Measurement for Cardiovascular Risk Assessment |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2021.181 | Description of evolocumab use among adults with established atherosclerotic cardiovascular disease or hypercholesterolemia in Asia-Pacific region – an observational study of clinical practice |
Prof. YAN Bryan Ping Yen 甄秉言教授 |
Page 238 of 254.